文献速递临床试验与 GCP流行病学与生物统计

埃博拉疫苗研究合作组织(PREVAC):在西非四国健康志愿者中评估三种埃博拉疫苗策略的随机双盲安慰剂对照2期临床试验方案

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
PubMed 文献 · Trials · 2021-01-23

PREVAC试验为随机双盲安慰剂对照2期临床试验,在几内亚、利比里亚、塞拉利昂和马里四国6个中心评估三种埃博拉疫苗策略在1岁及以上健康志愿者中的安全性和免疫原性。2017年4月至2018年12月共筛查5002人,入组4789人,其中成人2560人(53%)、儿童2229人(47%)。主要终点为末次注射后12个月抗埃博拉病毒表面糖蛋白抗体滴度。

要点

  • 三种疫苗策略:rVSVΔG-ZEBOV-GP单剂或56天加强,以及Ad26.ZEBOV/MVA-FN-Filo异源初免-加强。
  • 入组4789人,成人占53%,儿童占47%,含1-4岁、5-11岁和12-17岁三个年龄亚组。
  • 主要终点为末次注射后12个月抗埃博拉病毒表面糖蛋白抗体滴度。

核心结论

  • PREVAC试验正在评估两种处于后期开发阶段的埃博拉候选疫苗,采用安慰剂对照设计。
  • 结果将为三种疫苗策略在成人和儿童中的短期和长期安全性及免疫原性提供证据。

研究设计与样本

  • 随机、双盲、安慰剂对照2期临床试验,研究对象为1岁及以上健康志愿者。
  • 2017年4月至2018年12月在四个国家6个中心筛查5002人,入组4789人。
  • 入组者中成人2560人(53%),儿童2229人(47%)。
  • 儿童中亚组:1-4岁549人(12%)、5-11岁750人(16%)、12-17岁930人(19%)。
  • 方案共4个版本,版本4.0入组者构成主要分析队列。

主要发现

  • 1090名参与者基线抗埃博拉病毒糖蛋白抗体滴度中位数(第25、75百分位)为72(50,116)EU/mL。

关键数值与推荐

  • 主要终点基于末次注射后12个月测定的抗埃博拉病毒表面糖蛋白抗体滴度。
  • 研究疫苗策略包括rVSVΔG-ZEBOV-GP单剂、rVSVΔG-ZEBOV-GP加56天加强剂、以及Ad26.ZEBOV首剂后56天给予MVA-FN-Filo。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Ebola virus disease (EVD) outbreak in 2014-2016 in West Africa was the largest on record and provided an opportunity for large clinical trials and accelerated efforts to develop an effective and safe preventative vaccine. Multiple questions regarding the safety, immunogenicity, and efficacy of EVD vaccines remain unanswered. To address these gaps in the evidence base, the Partnership for Research on Ebola Vaccines (PREVAC) trial was designed. This paper describes the design, methods, and baseline results of the PREVAC trial and discusses challenges that led to different protocol amendments. METHODS: This is a randomized, double-blind, placebo-controlled phase 2 clinical trial of three vaccine strategies against the Ebola virus in healthy volunteers 1 year of age and above. The three vaccine strategies being studied are the rVSVΔG-ZEBOV-GP vaccine, with and without a booster dose at 56 days, and the Ad26.ZEBOV,MVA-FN-Filo vaccine regimen with Ad26.ZEBOV given as the first dose and the MVA-FN-Filo vaccination given 56 days later. There have been 4 versions of the protocol with those enrolled in Version 4.0 comprising the primary analysis cohort. The primary endpoint is based on the antibody titer against the Ebola virus surface glycoprotein measured 12 months following the final injection. RESULTS: From April 2017 to December 2018, a total of 5002 volunteers were screened and 4789 enrolled. Participants were enrolled at 6 sites in four countries (Guinea, Liberia, Sierra Leone, and Mali). Of the 4789 participants, 2560 (53%) were adults and 2229 (47%) were children. Those < 18 years of age included 549 (12%) aged 1 to 4 years, 750 (16%) 5 to 11 years, and 930 (19%) aged 12-17 years. At baseline, the median (25th, 75th percentile) antibody titer to Ebola virus glycoprotein for 1090 participants was 72 (50, 116) EU/mL. DISCUSSION: The PREVAC trial is evaluating-placebo-controlled-two promising Ebola candidate vaccines in advanced stages of development. The results will address unanswered questions related to short- and long-term safety and immunogenicity for three vaccine strategies in adults and children. TRIAL REGISTRATION: ClinicalTrials.gov NCT02876328 . Registered on 23 August 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Badio M, Lhomme E, Kieh M, et al. Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries. Trials. 2021. PMID: 33485369. doi:10.1186/s13063-021-05035-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。